Biogen Idec said its nerve-repair drug showed promise in a mid-stage clinical trial, an important step in the development of a multiple-sclerosis treatment that could reverse the disease instead of merely slowing down the symptoms.
via WSJ.com: US Business http://ift.tt/1wwtkvV
via WSJ.com: US Business http://ift.tt/1wwtkvV
Nessun commento:
Posta un commento